Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro

References

• Sheng J, Tran PN, Li Z, et al. Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity. J Pharmacol Toxicol Methods. 2017;88:109–122. doi:10.1016/j.vascn.2017.08.00628830713
   PubMed Web of Science ®Google Scholar
• Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, Backman JT. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol. 2006;62:463–472. doi:10.1007/s00228-006-0133-z16758263
   PubMed Web of Science ®Google Scholar
• Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother. 2005;49:4903–4910. doi:10.1128/AAC.49.12.4903-4910.200516304151
   PubMed Web of Science ®Google Scholar
• Jaffe JH, Kanzler M, Green J. Abuse potential of loperamide. Clin Pharmacol Ther. 1980;28:812–819. doi:10.1038/clpt.1980.2397438696
   PubMed Web of Science ®Google Scholar
• Miller H, Panahi L, Tapia D, Tran A, Bowman JD. Loperamide misuse and abuse. J Am Pharm Assoc. 2017;57:S45–S50. doi:10.1016/j.japh.2016.12.079
   Google Scholar
• Riaz IB, Khan MS, Kamal MU, et al. Cardiac dysrhythmias associated with substitutive use of loperamide: a systematic review. Am J Ther. 2017;26:170–182. doi:10.1097/MJT.0000000000000585
   Web of Science ®Google Scholar
• Katz KD, Cannon RD, Cook MD, et al. Loperamide-induced torsades de pointes: a case series. J Emerg Med. 2017;53:339–344. doi:10.1016/j.jemermed.2017.04.02728755998
   PubMed Web of Science ®Google Scholar
• Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 32nd annual report. Clin Toxicol (Phila). 2015;53:962–1147. doi:10.3109/15563650.2015.110292726624241
   PubMed Web of Science ®Google Scholar
• Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2017;69:83–86. doi:10.1016/j.annemergmed.2016.03.04727140747
   PubMed Web of Science ®Google Scholar
• Stefek B, Wolfe LT, Cohen M. Brugada syndrome associated with adolescent loperamide abuse. Pediatrics. 2018;142:e20181423. doi:10.1542/peds.2018-142330254039
   PubMed Web of Science ®Google Scholar
• Ruan X, Luo JJ, Kaye AD. Loperamide-related deaths in North Carolina. Med Leg J. 2017;85:55–56. doi:10.1177/002581721667211627678517
   PubMedGoogle Scholar
• Larsen TR, McMunn J, Ahmad H, AlMahameed ST. Ventricular tachycardia triggered by loperamide and famotidine abuse. Drug Saf Case Rep. 2018;5:11. doi:10.1007/s40800-018-0077-029455270
   PubMedGoogle Scholar
• Wu PE, Juurlink DN. Clinical review: loperamide toxicity. Ann Emerg Med. 2017;70:245–252. doi:10.1016/j.annemergmed.2017.04.00828506439
   PubMed Web of Science ®Google Scholar
• Dierksen J, Gonsoulin M, Walterscheid JP. Poor Man’s methadone: a case report of loperamide toxicity. Am J Forensic Med Pathol. 2015;36:268–270. doi:10.1097/PAF.000000000000020126355852
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA drug safety communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-heart-problems-high-doses-antidiarrheal. Accessed June, 2016.
   Google Scholar
• U.S. Food and DrugAdministration. FDA drug safety communication: FDA limits packaging for anti-diarrhea medicine loperamide (Imodium) to encourage safe use. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-packaging-anti-diarrhea-medicine-loperamide-imodium. Accessed January, 2018.
   Google Scholar
• Miyazaki H, Nambu K, Matsunaga Y, Hashimoto M. Disposition and metabolism of [14C]loperamide in rats. Eur J Drug Metab Pharmacokinet. 1979;4:199–206. doi:10.1007/BF3189427535599
   PubMedGoogle Scholar
• Yoshida K, Nambu K, Arakawa S, Miyazaki H, Hashimoto M. Metabolites of loperamide in rats. Biomed Mass Spectrom. 1979;6:253–259. doi:10.1002/bms.1200060606476289
   PubMedGoogle Scholar
• Vaz RJ, Kang J, Luo Y, Rampe D. Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K(+) channel. Bioorg Med Chem Lett. 2017;28:446–451. doi:10.1016/j.bmcl.2017.12.02029274816
   PubMed Web of Science ®Google Scholar
• Kim KA, Chung J, Jung DH, Park JY. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol. 2004;60:575–581. doi:10.1007/s00228-004-0815-315365656
   PubMed Web of Science ®Google Scholar
• Hu GX, Dai DP, Wang H, et al. Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics. 2017;18:369–379. doi:10.2217/pgs-2016-017928244811
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yu X, Shu C, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56:415–422. doi:10.1038/jhg.2011.3021412247
   PubMed Web of Science ®Google Scholar
• Nicolas JM, Espie P, Molimard M. Gender and interindividual variability in pharmacokinetics. Drug Metab Rev. 2009;41:408–421. doi:10.1080/1083745090289148519601720
   PubMed Web of Science ®Google Scholar
• Fang P, Tang PF, Xu RA, et al. Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro. Drug Des Devel Ther. 2017;11:3503–3510. doi:10.2147/DDDT.S152366
   PubMed Web of Science ®Google Scholar
• Yang CC, Zheng X, Liu TH, et al. Functional characterization of 21 CYP3A4 variants on amiodarone metabolism in vitro. Xenobiotica. 2019;49:120–126. doi:10.1080/00498254.2017.141497129394111
   PubMed Web of Science ®Google Scholar
• Zhou X-Y, Hu X-X, Wang C-C, et al. Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro. Front Pharmacol. 2019;10. doi:10.3389/fphar.2019.00591
   Web of Science ®Google Scholar
• Wilkinson GR. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin Pharmacol Ther. 2004;76:99–103. doi:10.1016/j.clpt.2004.04.00515289786
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373–388. doi:10.1097/00008571-200007000-0000110898107
   PubMedGoogle Scholar
• Klein MG, Haigney MCP, Mehler PS, Fatima N, Flagg TP, Krantz MJ. Potent inhibition of hERG channels by the over-the-counter antidiarrheal agent loperamide. JACC Clin Electrophysiol. 2016;2:784–789. doi:10.1016/j.jacep.2016.07.00829759761
   PubMedGoogle Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141. doi:10.1016/j.pharmthera.2012.12.00723333322
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Hermann R, Huennemeyer A, et al. Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin Pharmacol Ther. 2006;79:339–349. doi:10.1016/j.clpt.2005.11.01516580902
   PubMed Web of Science ®Google Scholar
• Apellaniz-Ruiz M, Inglada-Perez L, Naranjo ME, et al. High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme. Pharmacogenomics J. 2015;15:288–292. doi:10.1038/tpj.2014.6725348618
   PubMed Web of Science ®Google Scholar
• Xu RA, Wen J, Tang P, et al. Functional characterization of 22 CYP3A4 protein variants to metabolize ibrutinib in vitro. Basic Clin Pharmacol Toxicol. 2018;122:383–387. doi:10.1111/bcpt.1293429117640
   PubMed Web of Science ®Google Scholar
• Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825–831. doi:10.1111/bcpt.1293411714865
   PubMed Web of Science ®Google Scholar
• Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics. 2005;6:731–747. doi:10.2217/14622416.6.7.73116207150
   PubMed Web of Science ®Google Scholar
• Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268–273. doi:10.1016/S1359-6446(00)01678-011181494
   PubMed Web of Science ®Google Scholar
• Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem. 2004;279:38091–38094. doi:10.1074/jbc.C40029320015258162
   PubMed Web of Science ®Google Scholar
• Williams PA, Jose C, Dijana Matak V, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science. 2004;305:683–686. doi:10.1126/science.109973615256616
   PubMed Web of Science ®Google Scholar
• Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48–56. doi:10.1067/mcp.2000.10439110668853
   PubMed Web of Science ®Google Scholar
• Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001;11:447–458. doi:10.1097/00008571-200107000-0000811470997
   PubMedGoogle Scholar
• Hasemann CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochromes P450: acomparative analysis of three crystal structures. Structure. 1995;2:41–62. doi:10.1016/S0969-2126(01)00134-4
   Web of Science ®Google Scholar
• Werk AN, Cascorbi I. Functional gene variants of CYP3A4. Clin Pharmacol Ther. 2014;96:340–348. doi:10.1038/clpt.2014.12924926778
   PubMed Web of Science ®Google Scholar